Resistance to temozolomide (TMZ), the frontline chemotherapeutic agent for glioblastoma (GBM), has emerged as a formidable obstacle, underscoring the imperative to identify alternative therapeutic strategies to improve patient outcomes. In this study, we comprehensively evaluated a novel agent, O6-methyl-2′-deoxyguanosine-5′-triphosphate (O6-methyl-dGTP) for its anti-GBM activity both in vitro and in vivo. Notably, O6-methyl-dGTP exhibited pronounced cytotoxicity against GBM cells, including those resistant to TMZ and overexpressing O6-methylguanine-DNA methyltransferase (MGMT). Mechanistic investigations revealed that O6-methyl-dGTP could be incorporated into genomic DNA, disrupting nucleotide pools balance, and inducing replication stress, resulting in S-phase arrest and DNA damage. The compound exerted its anti-tumor properties through the activation of AIF-mediated apoptosis and the parthanatos pathway. In vivo studies using U251 and Ln229 cell xenografts supported the robust tumor-inhibitory capacity of O6-methyl-dGTP. In an orthotopic transplantation model with U87MG cells, O6-methyl-dGTP showcased marginally superior tumor-suppressive activity compared to TMZ. In summary, our research, for the first time, underscores the potential of O6-methyl-dGTP as an effective candidate against GBM, laying a robust scientific groundwork for its potential clinical adoption in GBM treatment regimens.

对胶质母细胞瘤 (GBM) 一线化疗药物替莫唑胺 (TMZ) 的耐药性已成为一个巨大的障碍，这凸显了寻找替代治疗策略以改善患者预后的必要性。在本研究中，我们综合评估了一种新型药物 O6-甲基-2′-脱氧鸟苷-5′-三磷酸 (O6-甲基-dGTP) 的体外抗 GBM 活性和体内。值得注意的是，O6-甲基-dGTP 对 GBM 细胞表现出明显的细胞毒性，包括对 TMZ 耐药和过表达 O6-甲基鸟嘌呤-DNA 甲基转移酶 (MGMT) 的细胞。机制研究表明，O6-甲基-dGTP 可以整合到基因组 DNA 中，破坏核苷酸库平衡，并诱导复制应激，导致 S 期停滞和 DNA 损伤。该化合物通过激活 AIF 介导的细胞凋亡和 parthanatos 途径发挥其抗肿瘤特性。使用 U251 和 Ln229 细胞异种移植物的体内研究支持了 O6-甲基-dGTP 强大的肿瘤抑制能力。在 U87MG 细胞的原位移植模型中，与 TMZ 相比，O6-甲基-dGTP 表现出稍微优越的肿瘤抑制活性。总之，我们的研究首次强调了 O6-甲基-dGTP 作为治疗 GBM 的有效候选药物的潜力，为其在 GBM 治疗方案中的潜在临床应用奠定了坚实的科学基础。